Boston Scientific Corporation
BSX
NYSE48.22
Boston Scientific Corporation
NYSE:BSX
RECENT
PRICE
48.22
P/E
RATIO
105.78
(PEG:-3.22)
P/E RATIO
RELATIVE
TO S&P
5.01
DIV
YLD
0.09%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
0.79 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 03/23:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Fiscal year
6.14
(2.81)
1.18
- -
5.62
(0.33)
0.38
- -
5.37
(1.36)
0.57
- -
5.43
(0.68)
0.31
- -
5.14
(0.70)
0.03
- -
5.05
0.29
0.47
- -
5.15
(2.89)
0.74
- -
5.33
(0.09)
0.62
- -
5.57
(0.09)
0.76
- -
5.57
(0.18)
0.26
- -
6.18
0.26
0.44
- -
6.60
0.08
0.81
- -
7.11
1.21
(0.00)
- -
7.71
3.38
0.99
- -
7.00
(0.06)
0.80
0.02
8.39
0.73
0.93
0.04
8.87
0.49
0.66
0.04
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.27
12.02
0.24
10.15
0.24
8.79
0.24
8.16
0.18
7.44
0.20
7.52
0.16
4.88
0.18
4.88
0.20
4.88
0.18
4.71
0.28
4.96
0.23
5.12
0.23
6.32
0.33
9.97
0.27
10.82
0.39
11.73
0.41
12.28
CAPEX per share
Book Value per share
1,273
1,487
1,499
1,508
1,518
1,509
1,407
1,341
1,324
1,341
1,358
1,370
1,381
1,392
1,417
1,417
1,431
Comm.Shares outs.(m)
- -
- -
- -
(44.5)
(2.57)
- -
(8.5)
(0.40)
- -
(13.5)
(0.19)
- -
(9.6)
(0.47)
- -
22.8
1.40
- -
(2.0)
(0.13)
- -
(106.1)
(6.23)
- -
(142.8)
(7.87)
- -
(95.8)
(4.78)
- -
82.9
3.74
- -
346.9
14.70
- -
26.5
1.06
- -
11.9
0.49
- -
(642.7)
(16.98)
0.05%
56.3
1.88
0.09%
86.1
4.06
0.09%
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (31/12/22 | Q4)
Total liabilities
$14,896 m.
Total assets
$32,469 m.
Long-term debt
$8,915 m.
Cash and equiv.
$928 m.
Goodwill $12,920 m.
Retained earnings $(750) m.
Common stock 1,433 m. shares
Market Capitalisation
$68,296 m. (as of 25/3/23)
7,622
11.9%
7,249
(53.4)%
7,143
1.7%
7,380
(4.1)%
7,477
(4.4)%
8,386
5.3%
9,048
14.2%
9,823
15.3%
10,735
14.1%
9,913
(0.8)%
11,888
10.1%
12,682
16.0%
Revenue (m)
Operating margin
717
441
683
(4,068)
689
(121)
725
(119)
769
(239)
815
347
844
104
894
1,671
1,011
4,700
1,123
(82)
1,093
1,041
803
698
Depreciation (m)
Net profit (m)
31.3%
5.8%
0.9%
(56.1)%
45.7%
(1.7)%
76.6%
(1.6)%
63.2%
(3.2)%
(96.0)%
4.1%
88.7%
1.1%
(17.5)%
17.0%
(584.1)%
43.8%
(2.5)%
(0.8)%
3.3%
8.8%
38.8%
5.5%
Income tax rate
Net profit margin
1,298
4,257
11,353
1,250
4,252
6,870
1,187
4,237
6,539
760
3,859
6,457
1,041
5,674
6,320
(348)
5,420
6,733
(1,832)
3,776
7,011
(1,257)
4,771
8,725
(167)
8,579
13,877
3,013
9,118
15,327
2,043
9,190
16,623
1,957
8,915
17,573
Working capital (m)
Long-term debt (m)
Equity (m)
3.3%
4.3%
3.9%
(24.8)%
(22.4)%
(59.2)%
0.4%
0.6%
(1.9)%
(0.5)%
(1.7)%
(1.8)%
(0.9)%
(2.0)%
(3.8)%
5.5%
2.3%
5.2%
1.0%
6.1%
1.5%
12.4%
7.9%
19.2%
30.9%
3.8%
33.9%
1.1%
0.9%
(0.5)%
4.9%
4.4%
6.3%
3.4%
5.0%
4.0%
ROIC
Return on capital
Return on equity
Working Capital
2020
2021
2022
Cash assets
1,734
1,925
928
Receivables
1,531
1,778
1,970
Inventory
1,351
1,610
1,867
Other
2,078
1,004
995
Current assets
6,694
6,317
5,760
Acc. Payable
513
794
862
Debt due
13
261
20
Other
3,155
3,219
2,921
Current liab.
3,681
4,274
3,803
100.0%
- -
100.0%
66.9%
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
(18.6)%
100.0%
(7.7)%
100.0%
1,683.3%
100.0%
(8.9)%
134.1%
- -
94.7%
4.2%
Plowback ratio
Div.&Repurch. to FCF
Boston Scientific Corporation (US) started trading on May 2, 1992 (cik: 0000885725), operates in the Healthcare sector (Medical Devices industry), has 41,000 full-time employees, and is led by Mr. Michael F. Mahoney. Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
7.06%
6.83%
Cash flow
-5761.70%
-2559.68%
Earnings
-330.73%
-3.58%
Dividends
- -
- -
Book value
20.92%
12.82%
Insider trading
Type
Shares
Date
Brennan Daniel J.
Sale
30,000
03/02/23
Monson Jonathan
Exempt
5,000
03/01/23
Monson Jonathan
Sale
5,000
03/01/23
Monson Jonathan
Exempt
5,000
03/01/23
Brennan Daniel J.
Exempt
13,661
03/01/23
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2020
2,543
2,003
2,659
2,709
9,914
2021
2,752
3,077
2,932
3,127
11,888
2022
3,026
3,244
3,170
3,242
12,682
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2020
0.01
(0.10)
(0.11)
0.15
-0.06
2021
0.24
0.13
0.30
0.07
0.73
2022
0.08
0.18
0.12
0.10
0.48
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2020
- -
- -
- -
0.01
0.01
2021
0.01
0.01
0.01
0.01
0.04
2022
0.01
0.01
0.01
0.01
0.04
08/08/2022
Boston Scientific Investigates Whistleblower Report in Vietnam
The Wall Street Journal - Read more...